Cybin Inc (CYBN)

$7.63 +0.37 (5.10%)
Market Cap 175.75M
Revenue (ttm) 0.00
Net Income (ttm) -81.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 324,400
Avg Vol 373,790
Day's Range N/A - N/A
Shares Out 23.59M
Stochastic %K 0%
Beta 0.68
Analysts Strong Sell
Price Target $78.80

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders; SPL...

Industry: Biotechnology
Sector: Healthcare
Address:
100 King Street West, Suite 5600, Toronto, Canada
cyriak2
cyriak2 Aug. 12 at 8:09 PM
$CYBN must have been some good news from the conference
1 · Reply
PsychedStocks
PsychedStocks Aug. 12 at 5:00 PM
$CYBN conference today at 2:30pm ET
1 · Reply
Buckwacker
Buckwacker Aug. 12 at 4:44 PM
$CYBN Alright where be we pre split, dime 😑??? WTF sitting on this for what three years now down 40 percent I’m trying to be bullish….
0 · Reply
McGuireTO
McGuireTO Aug. 11 at 9:10 PM
$CYBN - Click to watch the free video! Bearish close. Still within the range, 7.11 is key mid-long term support. 8.18 is a key short term resistance to give the first sign of shifting momentum. I post regular technical analysis of the psychedelics sector. Like and Follow to make sure you don't miss an update! https://www.tradingview.com/chart/CYBN/nhutRqW0-CYBN-red-marubozu-close/
0 · Reply
Profitsalways
Profitsalways Aug. 11 at 8:15 PM
$CYBN new monthly low, low volume, lower 🙏
0 · Reply
Bulltrader988
Bulltrader988 Aug. 10 at 12:19 PM
$CYBN tuesday 👃👀
0 · Reply
BelieveinthePK
BelieveinthePK Aug. 9 at 11:16 PM
$CYBN I’m bullish and will always be bullish on CYBN’s unique therapeutic innovation but my patience are running thin with each passing delay on their 004 top line results.
1 · Reply
Irichdialed
Irichdialed Aug. 9 at 5:59 PM
$CYBN When's a good time to buy this stock, will it go lower or is this the bottom? Otherwise I understand the market does not like this stock.. just feels like one day though these prices will be gone, even for this pos.
0 · Reply
UncleJudd
UncleJudd Aug. 9 at 4:07 PM
$CMPS $ATAI $CYBN $MNMD Psilocybin next? https://www.wsj.com/politics/policy/trump-marijuana-federal-drug-classification-01a73b8c
0 · Reply
Rico_Again_Jorge
Rico_Again_Jorge Aug. 9 at 3:51 PM
$CYBN I wished they managed to get it to $10 so I can short it again Shame
0 · Reply
Latest News on CYBN
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 7, 2025, 7:30 AM EDT - 5 days ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:30 AM EDT - 6 days ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 17, 2025, 7:30 AM EDT - 26 days ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 11:19 AM EDT - 6 weeks ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 10:03 PM EDT - 6 weeks ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 9:27 PM EDT - 6 weeks ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 13, 2025, 7:45 AM EDT - 2 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 12, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 11, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Jun 3, 2025, 7:30 AM EDT - 2 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 22, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 20, 2025, 7:30 AM EDT - 3 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 15, 2025, 7:30 AM EDT - 3 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 14, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 8, 2025, 7:30 AM EDT - 3 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin to Participate at the 28th Annual Milken Institute Global Conference

May 1, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 23, 2025, 7:30 AM EDT - 3 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Apr 21, 2025, 8:00 AM EDT - 4 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Feb 10, 2025, 9:48 PM EST - 6 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 15, 2025, 12:07 PM EST - 7 months ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 13, 2025, 7:30 AM EST - 7 months ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 9, 2025, 5:00 PM EST - 7 months ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 10, 2024, 7:30 AM EST - 8 months ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Dec 4, 2024, 7:30 AM EST - 8 months ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 18, 2024, 7:00 AM EST - 9 months ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 14, 2024, 7:30 AM EST - 9 months ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Nov 13, 2024, 7:30 AM EST - 9 months ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Oct 31, 2024, 7:30 AM EDT - 10 months ago

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Oct 24, 2024, 7:30 AM EDT - 10 months ago

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor +

Oct 18, 2024, 2:30 PM EDT - 10 months ago

Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor +

DAVA EQNR

Cybin: Top Value Psychedelic Stock

Oct 15, 2024, 12:30 PM EDT - 10 months ago

Cybin: Top Value Psychedelic Stock

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024

Oct 3, 2024, 7:30 AM EDT - 11 months ago

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

Oct 1, 2024, 7:30 AM EDT - 11 months ago

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics”

Sep 27, 2024, 11:48 AM EDT - 11 months ago

Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics”

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Sep 24, 2024, 7:30 AM EDT - 11 months ago

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Cybin Provides Corporate Update on Upcoming Clinical Milestones

Sep 19, 2024, 5:38 PM EDT - 11 months ago

Cybin Provides Corporate Update on Upcoming Clinical Milestones

'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale

Sep 19, 2024, 8:00 AM EDT - 11 months ago

'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale

Cybin Announces Completion of Previously Announced Share Consolidation

Sep 19, 2024, 7:26 AM EDT - 11 months ago

Cybin Announces Completion of Previously Announced Share Consolidation

Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 7:55 AM EDT - 1 year ago

Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

Aug 27, 2024, 7:01 PM EDT - 1 year ago

Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

Inovalis Real Estate Investment Trust Provides Supplemental Information in Connection With Its Upcoming Special Meeting of Unitholders to Be Held on September 4, 2024

Aug 27, 2024, 5:00 PM EDT - 1 year ago

Inovalis Real Estate Investment Trust Provides Supplemental Information in Connection With Its Upcoming Special Meeting of Unitholders to Be Held on September 4, 2024

V

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CMPS MNMD

Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Aug 8, 2024, 7:36 AM EDT - 1 year ago

Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 7, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference

A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update

Jul 8, 2024, 8:38 AM EDT - 1 year ago

A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update

Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights

Jun 26, 2024, 7:41 AM EDT - 1 year ago

Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights

Cilo Cybin becomes first medical cannabis company to list in South Africa

Jun 25, 2024, 10:19 AM EDT - 1 year ago

Cilo Cybin becomes first medical cannabis company to list in South Africa

Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 19, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development

Jun 11, 2024, 7:30 AM EDT - 1 year ago

Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development

cyriak2
cyriak2 Aug. 12 at 8:09 PM
$CYBN must have been some good news from the conference
1 · Reply
PsychedStocks
PsychedStocks Aug. 12 at 5:00 PM
$CYBN conference today at 2:30pm ET
1 · Reply
Buckwacker
Buckwacker Aug. 12 at 4:44 PM
$CYBN Alright where be we pre split, dime 😑??? WTF sitting on this for what three years now down 40 percent I’m trying to be bullish….
0 · Reply
McGuireTO
McGuireTO Aug. 11 at 9:10 PM
$CYBN - Click to watch the free video! Bearish close. Still within the range, 7.11 is key mid-long term support. 8.18 is a key short term resistance to give the first sign of shifting momentum. I post regular technical analysis of the psychedelics sector. Like and Follow to make sure you don't miss an update! https://www.tradingview.com/chart/CYBN/nhutRqW0-CYBN-red-marubozu-close/
0 · Reply
Profitsalways
Profitsalways Aug. 11 at 8:15 PM
$CYBN new monthly low, low volume, lower 🙏
0 · Reply
Bulltrader988
Bulltrader988 Aug. 10 at 12:19 PM
$CYBN tuesday 👃👀
0 · Reply
BelieveinthePK
BelieveinthePK Aug. 9 at 11:16 PM
$CYBN I’m bullish and will always be bullish on CYBN’s unique therapeutic innovation but my patience are running thin with each passing delay on their 004 top line results.
1 · Reply
Irichdialed
Irichdialed Aug. 9 at 5:59 PM
$CYBN When's a good time to buy this stock, will it go lower or is this the bottom? Otherwise I understand the market does not like this stock.. just feels like one day though these prices will be gone, even for this pos.
0 · Reply
UncleJudd
UncleJudd Aug. 9 at 4:07 PM
$CMPS $ATAI $CYBN $MNMD Psilocybin next? https://www.wsj.com/politics/policy/trump-marijuana-federal-drug-classification-01a73b8c
0 · Reply
Rico_Again_Jorge
Rico_Again_Jorge Aug. 9 at 3:51 PM
$CYBN I wished they managed to get it to $10 so I can short it again Shame
0 · Reply
Rico_Again_Jorge
Rico_Again_Jorge Aug. 9 at 3:51 PM
$CYBN This is still so
0 · Reply
TimRegan_WTR
TimRegan_WTR Aug. 8 at 4:10 PM
$CYBN
0 · Reply
sam2680
sam2680 Aug. 8 at 3:26 PM
$CYBN Financial report Q2 expected to be released near Aug 14
0 · Reply
research_WTR
research_WTR Aug. 8 at 3:13 PM
Cybin Inc secures EU green light for EMBRACE Phase 3 trial ✅ — advancing its CYB003 program for major depressive disorder. 🔹 Irish Medicines Board approves CTA, enabling trial launch in Ireland, Poland & Greece 🔹 EMBRACE to enroll 330 patients across 60 sites in the US, Europe & Australia 🔹 APPROACH pivotal study & EXTEND open-label extension for long-term evaluation underway 🔹 Near-term catalyst: CYB004 anxiety trial readout expected this summer Check out Robert Sassoon's full report for more! https://www.watertowerresearch.com/doc?docID=UR_CYBN_08072025 $CYBN #MentalHealth #ClinicalTrials #Biotech #MDD #DepressionTreatment #PharmaNews #Cybin #WTRSpotlight
0 · Reply
microdoseme
microdoseme Aug. 8 at 2:46 PM
$CYBN I have the 18th for ER
0 · Reply
TalesfromtheF
TalesfromtheF Aug. 8 at 1:58 PM
$CYBN late with their ER again. This needs to stop, it makes them look unserious
0 · Reply
microdoseme
microdoseme Aug. 8 at 1:01 PM
$CYBN Nice read...Final Thought ....Psychedelic therapy, when approached with intention, guidance, and follow-through, offers more than just momentary relief. It offers a pause in the automatic. A glimpse of possibility. And the chance to reshape your internal landscape, not in one bold swoop, but in repeated, mindful turns down the mountain.
0 · Reply
microdoseme
microdoseme Aug. 8 at 12:54 PM
$CYBN https://www.psychologytoday.com/us/blog/psychedelics-to-the-rescue/202508/how-psychedelics-unlock-neuroplasticity-for-healing
0 · Reply
McGuireTO
McGuireTO Aug. 7 at 8:24 PM
Looks like $CYBN ER is next Thursday. TradingView was wrong.... jerks https://www.nasdaq.com/market-activity/stocks/cybn/earnings
0 · Reply
theflynews
theflynews Aug. 7 at 2:55 PM
Psychedelic: Cybin receives European approval for EMBRACE study - $CYBN - https://thefly.com/permalinks/entry.php/CYBNid4178497?1754577930C
0 · Reply
HughJasol
HughJasol Aug. 7 at 1:23 PM
$CYBN wow great news… It will be red again.
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 7 at 11:56 AM
$CYBN long term play with pt 80. very undervalued.
1 · Reply